VAI Scores and Anti-VEGF Treatment Response in Diabetic Macular Edema

298 patients with type 2 diabetes and center-involved diabetic macular edema were analyzed in a retrospective cohort study from 2022 to 2023. The data examines the association between baseline Visceral Adiposity Index scores and resistance to anti-VEGF therapy, with 47.0% of patients classified as non-responders.

Use Cases

• Train a logistic regression model to predict treatment resistance (non-responder status) using baseline VAI scores and other confounders
• Perform Kaplan-Meier survival analysis on time-to-positive-response data segmented by the VAI cut-off of 2.50
• Calculate prognostic performance metrics like AUC using VAI scores and the defined functional response outcome

Strengths

• Data from 298 patient records provides a substantive clinical cohort for analysis
• Study includes a defined temporal coverage from January 2022 to December 2023
• Key outcome metrics like Adjusted Odds Ratio (0.71) and AUC (0.73) are reported for model validation

Limitations

• Dataset scope is limited to 16.2 KB, indicating it contains summary results rather than raw patient-level data
• The retrospective study design may introduce selection bias or unmeasured confounding factors
• Specific patient-level columns and sample data are unavailable, restricting detailed feature engineering

Provenance

Source

figshare, author Mi Chen

Collection Method

Retrospective cohort study analyzing patient records

Time Range

January 2022 to December 2023

Freshness

null

Geography

null